The medicines, for children under the age of two, are being pulled off shelves and being sold under restricted conditions as parents in the UK are being warned about the dangers of giving toddlers potentially fatal overdoses.
Several ingredients commonly used in cough and cold medication will also no longer be licensed for children under two.
And while these measures are being implemented in the UK, the medication is still available locally over the counter.
A local pharmacist, who did not want to be named, said a label on a remedy he picked up randomly from a shelf, containing one of the ingredients listed, read that it could be used for children aged one to five.
"In a case like this, the manufacturers would have to revise the packaging and the dosage," he said.
"And if the ingredients are being banned for children under the age of two for safety reasons, then the Medicines Control Council (MCC) will act swiftly."
In the UK, the deaths of at least five toddlers have been linked to cough and cold remedies.
At least 100 products will now be put under the counter as parents are warned about the danger of giving toddlers potentially fatal overdoses, the Daily Mail reported.
The products will now be sold from under the counter and removed from open sale. They will be sold only after specific instructions from pharmacists regarding dosages for use with children older than two.
Mandisa Hela, head of the MCC, said that in general many of the products listed, and those with the potentially dangerous ingredients, are not allowed for children under the age of two.
"When the decision not to allow their use in the US and UK was announced, many of the manufacturers voluntarily changed the age limit or changed the formulation (of the medication)," she said.
"The MCC is, however, still assessing this whole area. Once this is completed, a statement will be issued to the public."
According to the Daily Mail, at least five deaths of British children under two have been linked to cough and cold remedies and more than 100 serious cases of suspected adverse reactions have been reported.
Six products directly targeted at children under the age of two are being removed from open sale. A further 59 products - authorised for use in children under the age of two but not marketed at them - will also be removed from shelves and sold only to parents whose children are older.
Another 58 products aimed only at children aged two to six will also be taken down.